Qiming Corporate GP VI, Ltd. sold $2.9M of ALMR (indirect holdings)
Qiming Corporate GP VI, Ltd. sold 100,117 indirectly-held shares of Alamar Biosciences, Inc. (ALMR) at an average of $29.38 ($29.34–$30.63, $2.94M total) across 8 trades on 2026-11-11. Filed jointly with Qiming Managing Directors Fund VI, L.P. (10% owner), Qiming Venture Partners VI, L.P. (10% owner), Qiming GP VIII, LLC (10% owner), Qiming Venture Partners VIII Investments, LLC (10% owner), Qiming GP VIII-HC, LLC (10% owner) and Qiming Venture Partners VIII-HC, L.P. (10% owner).
How this was made
The 30-second read
Why it matters
The reduction of a large insider stake may be interpreted as a bearish sign, but could also reflect normal portfolio management.
Market read
A primary insider sale filing with modest dollar size; likely limited but measurable impact on ALMR's short‑term price.
What to watch
Potential tax‑loss harvesting or liquidity needs for the investor may drive the sale, not company fundamentals.
Background
SEC Form 4 filings disclose insider transactions; this filing reports a direct market sale by a 10% owner of ALMR.
Ticker impact
Form 4 shows Qiming Corporate GP VI, Ltd. sold ~2.9M USD of ALMR shares, reducing its stake to 1.63M shares.
likely modest downward pressure as the market prices the insider sell.
The sale is sizable relative to the insider's remaining holdings and was executed at market prices, indicating possible lack of confidence.
Market effects
Minimal impact on the broader biotech sector; the transaction is company‑specific.
No significant regional effect; the filing is U.S. SEC‑based.
Limited global relevance beyond investors tracking ALMR.
Counterpoint
The sale could be a routine portfolio rebalancing rather than a negative signal.
Key entities
- companyAlamar Biosciences, Inc.
Biotech firm listed on NASDAQ under ticker ALMR.
- investorQiming Corporate GP VI, Ltd.
10% owner of ALMR that executed the share sale.



